Skip to content

Healthcare Professional Confirmation

The information on the page you are about to enter is intended for Healthcare Professionals only.

Return to the Patient Website

Man standing in front of a food truck

Faster Recovery. Fewer Risks. Proven Outcomes.

Doctor talking to a patient

Clinical Results

Clinical results from over 28 peer-reviewed publications demonstrate that treatment with the UroLift System offers rapid and significant improvements in symptoms, urinary flow and quality of life sustained through five years.1 Compared to medications, the UroLift System has demonstrated a more positive effect on quality of life for patients.1 The UroLift System treatment preserves sexual function and avoids complications typically associated with other BPH procedures.1,2,4,21*

“The UroLift clinical publication record is flawless. Every patient treated under a clinical protocol appears in at least one peer-reviewed publication. The outcomes from the numerous studies are consistent, demonstrating rapid relief within two weeks and sustained improvement in symptoms, quality of life and urinary flow.”

Claus Roehrborn, MD, Urologist, USA

*Dr Roehrborn is a paid consultant of Neotract|Teleflex

UroLift System Treatment Delivers a Superior Patient Experience:

Checkmark

Rapid relief and recovery3,4

Checkmark

Lowest catheter rate of the leading BPH procedures1,3,5,21-23

Checkmark

No new, sustained erectile or ejaculatory dysfunction2,4,21*

Checkmark

Proven durability through five years1

Redefining BPH Treatment

Most patients living with BPH take prescription medications, but these medications can become a lifelong burden. In a recent men’s health survey, two out of three patients reported frustration with their current BPH prescription.7 These patients have been unwilling to consider a surgical procedure due to the perceived risks and invasive nature of the standard options.

Now, urologists can offer men the UroLift System treatment—a BPH solution with a low risk profile to improve their patient’s quality of life.4

Redefining Minimally Invasive BPH Treatment

Watchful waiting, medical therapy, and surgery/procedure statistics

15 million men in Europe are treated for BPH/LUTS1

The UroLift™ System is a proven option for patients seeking an alternative to BPH medications.2

  1. Neotract OUS market model estimates for 2022.
  2. Roehrborn, Can J Urol 2017

What Patients Want: A Better Experience

Patients on BPH Medications Are Not Satisfied

  • 48% of patients on medications do not have a clinically significant improvement in symptoms (< 4 point IPSS improvement)8
  • 5ARI drugs take three to six months for symptom relief9,10
  • Side-effects include headaches, dizziness, asthenia, nasal congestion, loss of libido, ejaculatory dysfunction, and erectile dysfunction2

Surgery is a Big Step for Patients

  • Surgery with general anesthesia comes with operative risks: transfusion, significant hematuria2
  • Catheterization for days5
  • Four to six weeks irritative voiding symptoms and recovery2,11-13
  • Risk of permanent complications2
    • Urinary incontinence
    • Sexual dysfunction
    • Urethral stricture

Even Watchful Waiting Comes with Risks

  • Bladder outlet obstruction may result in irreversible bladder damage if left untreated14,15
  • 87% of men who elect watchful waiting experience a worsening of symptoms over a four year time period16
  • Men who delay TURP with watchful waiting have significantly worse outcomes than those who had TURP sooner17

Preservation of Sexual Function is Important to BPH Patients

In a global survey of 13,618 men age 40-80 across 29 countries, 23.8%-74.6% rated sex as being very to extremely important.18 Erectile dysfunction contributes to anxiety, depression, loss of self-esteem and diminished quality of life so preserving erectile function significantly impacts quality of life in BPH patients.19 In choosing a BPH treatment, it is important to consider the impact ejaculatory dysfunction and sexual function has on patient satisfaction.

 

The UroLift System Treatment: The Only Leading BPH Procedure Shown Not to Cause New and Lasting Sexual Dysfunction*2,4,21,

*no new onset, sustained erectile or ejaculatory disfunction

Sexual Dysfunction Rate chart

Five Year Data Demonstrates That Outcomes Are Rapid, Durable and Reproducible


IPSS Improvement

Improvement in LUTS, as seen through average reduction in IPSS (International Prostate Symptom Score), has been consistent across the various studies, showing rapid relief within two weeks and sustained effect through five years.1 IPSS improvement at one year is better than seen with medications.2,4

Quality of Life Improvement

Quality of life also improved significantly, with the IPSS QOL and BPH Impact Index maintaining 50% and 52% improvements, respectively at five years, p<0.0001.1

Flow Rate Improvement

In addition to improving LUTS, the UroLift System treatment has demonstrated significant average improvement in peak urinary flow rate (Qmax) of 3.5 mL/sec (44%) that was sustained to five years, p<0.0001.1

Low Retreatment Rate

The rate of surgical intervention for failure to cure with the UroLift System remains low for a BPH procedure, with approximately 13.6% over five years or about 2-3% per year.1 Over the first postoperative year, no additional surgical intervention was required for bladder neck contracture, bleeding, or stress incontinence in the pivotal study on UroLift System.4


Surgical Reteatment Rates chart

References

  • 1. Roehrborn et al. Can J Urol 2017

  • 2. AUA Guidelines 2003

  • 3. Shore, Can J Urol 2014

  • 4. Roehrborn, J Urology 2013

  • 5. Bachmann, Eur Urol 2014 May

  • 6. NeoTract US Market Model estimates for 2020, data on file.

  • 7. Men's health survey, 2018

  • 8. Wei, et al, J Urol April 2010; AUA 2010 abstract

  • 9. Pearson, Am Fam Physician 2014

  • 10. Cindolo, Eur Urol Sep 2015

  • 11. Miano, Med Sci Mont 2008

  • 12. Wasson, Perspectives in Nursing 2000

  • 13. NIH U.S. National Library of Medicine – TURP patient instructions

  • 14. Tubaro, Drugs Aging 2003

  • 15. Mirone, Eur Urol 2007

  • 16. Djavan, Urology 2004

  • 17. Flanigan, J Urol 1998

  • 18. Laumann, Arch Sex Beh April 2006

  • 19. Carbone, Int J Impot Res 2003

  • 20. NeoTract Taking Share Survey July 2016 Update; data on file

  • 21. McVary, J Urol 2016

  • 22. Mollengarden, Prostate Cancer Prostatic Dis 2018

  • 23. Gilling, J Urol 2017

  • *No instances of new, sustained erectile or ejaculatory dysfunction in the LIFT pivotal study

  • ** Dr Roehrborn is a paid consultant of Neotract | Teleflex